Introduction {#tca12425-sec-0005}
============

Lung cancer is the main cause of cancer‐related death around the world, with about 1.4 million deaths worldwide each year. Non‐small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases.[1](#tca12425-bib-0001){ref-type="ref"} Although some advances have been achieved in treatments, lung cancer has an extremely poor prognosis, with a five‐year overall survival (OS) of 16% in the United States and less than 10% in the United Kingdom.[2](#tca12425-bib-0002){ref-type="ref"} Alone or in combination, the prognostic factors are variable measured indicators of individual patients, which may explain part of the population heterogeneity and provide information on clinical outcomes at the time of diagnosis. The tumor node metastasis (TNM) stage is thought to have an effect on survival in NSCLC patients; however, problems such as similar prognoses for patients with different tumor stages and varied prognoses for patients with the same tumor stage have been indicated. Recent research has revealed that some biological markers may have an impact on survival in NSCLC patients.[3](#tca12425-bib-0003){ref-type="ref"}, [4](#tca12425-bib-0004){ref-type="ref"}, [5](#tca12425-bib-0005){ref-type="ref"}

Phosphatase and tensin homolog (*PTEN*), also known as mutated in multiple advanced cancer 1 (MMAC1) or TGF‐βregulated and epithelial cell‐enriched phosphatase 1 (TEP1), is a 47 kDa dual specific protein‐phospholipid phosphatase, which was first identified as a tumor suppressor gene located at chromosome 10q23.3 by three separate groups of investigators in 1997.[6](#tca12425-bib-0006){ref-type="ref"}, [7](#tca12425-bib-0007){ref-type="ref"}, [8](#tca12425-bib-0008){ref-type="ref"} *PTEN* is an important negative regulator of the protein kinase B/phosphatidylinositol 3‐kinase (PI3K) pathway, which is one of the most important pathways for cell growth, proliferation, and survival, by dephosphorylating phosphatidylinositol 3,4,5‐triphosphate (PIP3) at its D3 position.[9](#tca12425-bib-0009){ref-type="ref"}, [10](#tca12425-bib-0010){ref-type="ref"}, [11](#tca12425-bib-0011){ref-type="ref"}, [12](#tca12425-bib-0012){ref-type="ref"} It has also been suggested that *PTEN* regulates focal adhesion structure and cell invasion and migration by controlling focal adhesion kinase (FAK) activity.[13](#tca12425-bib-0013){ref-type="ref"}, [14](#tca12425-bib-0014){ref-type="ref"} In addition, *PTEN* can restrict cellular differentiation by decreasing the activation of mitogen‐activated protein kinase (MAPK).[15](#tca12425-bib-0015){ref-type="ref"}, [16](#tca12425-bib-0016){ref-type="ref"} *PTEN* may also inhibit angiogenesis by downregulating both hypoxia‐inducible factor‐1 alpha (HIF‐1 alpha) and vascular endothelial growth factor (VEGF) in tumor cells.[17](#tca12425-bib-0017){ref-type="ref"}, [18](#tca12425-bib-0018){ref-type="ref"} Recently, many studies have indicated that *PTEN* is related to survival in patients with malignant tumors, including esophageal squamous cell carcinoma,[19](#tca12425-bib-0019){ref-type="ref"} acute myeloid leukemia,[20](#tca12425-bib-0020){ref-type="ref"} and breast,[21](#tca12425-bib-0021){ref-type="ref"} prostate,[22](#tca12425-bib-0022){ref-type="ref"} and gastric cancers.[23](#tca12425-bib-0023){ref-type="ref"} However, the results relating to the prognostic role of PTEN expression in NSCLC are inconsistent among clinical studies; therefore, a systematic review and meta‐analysis based on the published literature is necessary to provide further insights into this conflicting issue.

The aim of our study was to identify the prognostic value of PTEN expression in NSCLC patients. We also investigated the correlation between PTEN expression and clinicopathological characteristics.

Methods {#tca12425-sec-0006}
=======

This systematic review and meta‐analysis was performed according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) Statement protocol.[24](#tca12425-bib-0024){ref-type="ref"}

Search strategy {#tca12425-sec-0007}
---------------

We searched MEDLINE (via PubMed), Embase (via OVID), CENTRAL (via the Cochrane Library), and the Chinese BioMedical Literature Database (CBM) to October 2016 to identify studies relevant to this review. Our search strategy included the following subject headings and/or keywords variably combined by "lung neoplasm," "PTEN," and "prognosis." The detailed PubMed search strategy is shown in Figure [1](#tca12425-fig-0001){ref-type="fig"}. In addition, reference lists of the articles initially detected were searched manually to identify additional relevant reports. The eligibility of references retrieved by the search was assessed independently by two of the authors, and the review authors resolved differences of opinion by discussion or by appeal to a third review author when necessary. The full text of the remaining articles, including the references, was examined to determine whether the articles contained relevant information.

![PubMed search strategy. PTEN, phosphatase and tensin homolog.](TCA-8-203-g005){#tca12425-fig-0001}

Inclusion and exclusion criteria {#tca12425-sec-0008}
--------------------------------

Studies were considered eligible if they met all of the following inclusion criteria: (i) the study population consisted of primary NSCLC patients; (ii) PTEN expression was evaluated in primary lung carcinoma tissues by immunohistochemistry (IHC), reverse‐transcriptase (RT)‐PCR, or fluorescence in situ hybridization (FISH); and (iii) the association between PTEN expression and OS and disease‐free survival (DFS) were measured and/or the associations of PTEN expression and clinical characteristics was reported. Studies were excluded based on any of the following criteria: (i) reviews, letters, laboratory research, and animal experiments were excluded; (ii) the language was not English or Chinese; or (iii) the study lacked critical data for hazard ratio (HR) analysis.

Quality assessment {#tca12425-sec-0009}
------------------

Quality assessment of individual studies was performed independently by two of the authors, using the Newcastle--Ottawa Scale (NOS) for cohort studies. The scale allocates stars (maximum of 9) for quality of selection, comparability, and outcome of study participants.[25](#tca12425-bib-0025){ref-type="ref"} NOS scores of \>6 were defined as high‐quality studies. Any discrepancies were addressed by joint reevaluation of the original article.

Data extraction {#tca12425-sec-0010}
---------------

Data were extracted from the selected studies independently by two of the authors, using a predefined standardized form and disagreements were resolved by discussion between two review authors or by appealing to a third review author. The original data included PTEN expression, Kaplan--Meier (K--M) survival curves, or HR and 95% confidence interval (CI) of survival outcomes. Multivariate Cox hazard regression analysis data was our priority, but if not obtained, univariate Cox hazard regression analysis or K--M survival curves with log‐rank *P* value of survival outcomes were used instead. Because HRs were not available in all of the included studies, we calculated the HR with 95% CI using survival rates, enrolled samples, and corresponding *P* values from log‐rank test in accordance with the described instructions. The relevant formulas are as follows: $$O - E = \frac{\sqrt{\textit{Total observed events} \times \textit{Analyzed research} \times \textit{Analyzed control}}}{\left( {\text{Analyzed research} + \text{Analyzed control}} \right)} \times \left( {Z\mspace{2mu}\text{score}\mspace{2mu}{for}\mspace{2mu} P\mspace{2mu}\text{value}/2} \right)$$ $$V = \frac{\text{Total observed events} \times \text{Analyzed research} \times \text{Analyzed control}}{\left( {\text{Analyzed research} + \text{Analyzed control}} \right)^{2}}$$ $$\mathit{HR} = {Exp}\left( {- \frac{O - E}{V}} \right)$$

where O − E is the log rank Observed minus Expected events and V is the log rank Variance.[26](#tca12425-bib-0026){ref-type="ref"} We then extracted the associated details by Engauge Digitizer 4.1 (<http://sourceforge.net>) from the K‐M curves to measure the accuracy of estimated HRs. We extracted basic characteristics, including first author (year), primary treatment, country, study period, study design, number of patients, number of patients with evaluated PTEN expression and/or survival data, stage, method, cut‐off/scoring categories, antibody, median follow‐up, patients' average age when diagnosed with lung cancer, histology, and attitude conclusion from eligible articles.

Statistical analysis {#tca12425-sec-0011}
--------------------

The log HR was chosen as the appropriate summary statistic because it was the only summary statistic that allowed for both censoring and time to an event.[27](#tca12425-bib-0027){ref-type="ref"} However, these relevant statistical variables were not explicitly provided in most studies; therefore, we extracted associated data from K--M survival curves. We carried out meta‐analysis on PTEN expression in NSCLC cells for OS and DFS. We also analyzed correlations between PTEN expression and clinical characteristics, including age, gender, grade, smoking history, histology, primary tumor (pT) stage, TNM stage, lymph node metastasis, and other characteristics. According to clinical characteristics, stages I and II, stages III and IV, T2, T3, and T4 were combined, while well‐differentiated (G1) and moderately differentiated (G2) were combined and poorly differentiated (G3) was separated. Their correlations were described by odds ratio (OR). The effects of PTEN expression on survival outcome (OS/DFS) and correlations between PTEN expression and clinical characteristics were estimated by forest plots. Heterogeneity was defined as *P* \< 0.10 or I^2^ \> 50%. When homogeneity was good (*P* \> 0.10, I^2^ \< 50%), a fixed effect model was used to combine effective sizes, otherwise a random effect model was used. Subgroup analyses were performed to investigate the potential causes of heterogeneity according to region, sample size, follow‐up period, test methods, and NOS scores. Meta‐regression was also used to identify the source of heterogeneity. An observed HR \> 1 indicated a worse outcome for the positive group compared with the negative group and was considered significant if the 95% CI did not overlap 1. The potential publication bias was evaluated by Begg\'s rank correlation and Egger\'s test, with *P* \> 0.05 indicating no potential publication bias.[28](#tca12425-bib-0028){ref-type="ref"} Meta‐analysis and publication biases were both performed by STATA 13.0 (STATA Corporation, College Station, TX, USA).

Results {#tca12425-sec-0012}
=======

Reference retrieval {#tca12425-sec-0013}
-------------------

After primary retrieval, a total of 231 potentially relevant studies were initially incorporated into our study, including 121 from MEDLINE, 89 from Embase, 17 from CBM, 1 from CENTRAL, and 3 from reference lists. Forty were excluded as duplicates and 151 were excluded by title/abstract screening. Full texts were retrieved for the remaining 40 studies. Nineteen retrospective trials finally met all of the criteria for inclusion in the analysis, which included 3071 patients with a median number of 161.6 patients per study (Fig [2](#tca12425-fig-0002){ref-type="fig"}).

![Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow diagram for selection of studies. HR, hazard ratio; PTEN, phosphatase and tensin homolog.](TCA-8-203-g002){#tca12425-fig-0002}

Characteristics and qualities of the included studies {#tca12425-sec-0014}
-----------------------------------------------------

The clinical characteristics of the patients are listed in Table [1](#tca12425-tbl-0001){ref-type="table-wrap"}. All of the studies were published after 2005. Only one study was a multinational study undertaken in 30 different countries, while the other 18 studies were single‐center studies (14 in Asian countries and 4 in Western countries).[39](#tca12425-bib-0039){ref-type="ref"} NSCLC trials included either all histological subtypes[29](#tca12425-bib-0029){ref-type="ref"}, [30](#tca12425-bib-0030){ref-type="ref"}, [31](#tca12425-bib-0031){ref-type="ref"}, [32](#tca12425-bib-0032){ref-type="ref"}, [33](#tca12425-bib-0033){ref-type="ref"}, [35](#tca12425-bib-0035){ref-type="ref"}, [36](#tca12425-bib-0036){ref-type="ref"}, [37](#tca12425-bib-0037){ref-type="ref"}, [38](#tca12425-bib-0038){ref-type="ref"}, [39](#tca12425-bib-0039){ref-type="ref"}, [40](#tca12425-bib-0040){ref-type="ref"}, [41](#tca12425-bib-0041){ref-type="ref"}, [43](#tca12425-bib-0043){ref-type="ref"}, [44](#tca12425-bib-0044){ref-type="ref"}, [45](#tca12425-bib-0045){ref-type="ref"}, [46](#tca12425-bib-0046){ref-type="ref"}, [47](#tca12425-bib-0047){ref-type="ref"} (*n* = 17), or adenocarcinoma (ADC) (*n* = 2).[34](#tca12425-bib-0034){ref-type="ref"}, [42](#tca12425-bib-0042){ref-type="ref"} Data related to local advanced disease (stages I--III) comprised three of the 19 NSCLC trials,[32](#tca12425-bib-0032){ref-type="ref"}, [36](#tca12425-bib-0036){ref-type="ref"}, [42](#tca12425-bib-0042){ref-type="ref"} while 13 studies dealt with any stage (I--IV).[29](#tca12425-bib-0029){ref-type="ref"}, [31](#tca12425-bib-0031){ref-type="ref"}, [33](#tca12425-bib-0033){ref-type="ref"}, [34](#tca12425-bib-0034){ref-type="ref"}, [35](#tca12425-bib-0035){ref-type="ref"}, [37](#tca12425-bib-0037){ref-type="ref"}, [38](#tca12425-bib-0038){ref-type="ref"}, [40](#tca12425-bib-0040){ref-type="ref"}, [41](#tca12425-bib-0041){ref-type="ref"}, [43](#tca12425-bib-0043){ref-type="ref"}, [44](#tca12425-bib-0044){ref-type="ref"}, [46](#tca12425-bib-0046){ref-type="ref"}, [47](#tca12425-bib-0047){ref-type="ref"} Shin *et al*. assessed local early disease stage (I).[30](#tca12425-bib-0030){ref-type="ref"} O\'Byrne *et al*. only involved patients with stages III--IV disease and the patients were separated into to two groups according to different treatments (chemotherapy and chemotherapy + cetuximab).[39](#tca12425-bib-0039){ref-type="ref"} In Lim *et al*.\'s study, patients were divided into two groups on the basis of different stage and treatment (stage I treated with surgery and stage IV treated with gefitinib).[45](#tca12425-bib-0045){ref-type="ref"}

###### 

Baseline characteristics of included studies

  Study (year)                                                                                             Country        Study period   Study design   NOS   N     n     Primary treatment    Stage     Histology   Method   Cut‐off/ scoring categories   Antibody   Follow‐up (months)   Age (years)                          Survival Outcome   Attitude            
  -------------------------------------------------------------------------------------------------------- -------------- -------------- -------------- ----- ----- ----- -------------------- --------- ----------- -------- ----------------------------- ---------- -------------------- ------------------------------------ ------------------ ---------- -------- ----------
  Wang *et al.* 2015[29](#tca12425-bib-0029){ref-type="ref"}                                               China          2004--2010     ROS            7     92    92    Surgery              I--IV     52          34       6                             IHC        Scoring = 2          Monoclonal, mouse anti‐human PTEN    28                 23--83     OS       Positive
  Shin *et al.* 2015[30](#tca12425-bib-0030){ref-type="ref"}                                               Korea          2000--2005     ROS            6     408   250   Surgery              I         250         158      ‐                             IHC        Scoring = 1          NR                                   NR                 62.1       OS       Positive
  Li *et al.* 2015[31](#tca12425-bib-0031){ref-type="ref"}                                                 China          2004--2006     ROS            6     68    68    Surgery              I--IV     32          36       ‐                             IHC        74%                  Monoclonal, rabbit anti‐human PTEN   15.8               64         OS       Positive
  Ji *et al.* 2014[32](#tca12425-bib-0032){ref-type="ref"}                                                 China          2007--2008     ROS            6     67    67    Surgery              I--III    31          28       8                             IHC        5%                   Monoclonal, mouse anti‐human PTEN    NR                 39--80     OS       Positive
  Yoo.*et al.* 2013[33](#tca12425-bib-0033){ref-type="ref"}                                                Korea          2003--2009     ROS            6     41    41    Surgery              I‐IV      36          2        3                             IHC        50%                  NR                                   NR                 59         DFS      Positive
  Yanagawa *et al.* 2012[34](#tca12425-bib-0034){ref-type="ref"}                                           Canada         2005--2009     ROS            6     152   152   Surgery              I--IV     94          44       14                            IHC        0%                   Monoclonal, rabbit anti‐human PTEN   28.6               66.9       DFS      Positive
  Wang *et al.* 2012[35](#tca12425-bib-0035){ref-type="ref"}                                               China          2006--2007     ROS            6     78    78    Surgery              I--IV     34          44       --                            IHC        Scoring = 2          Polyclonal, rabbit anti‐human PTEN   NR                 NR         DFS      Positive
  Kim *et al.* 2012[36](#tca12425-bib-0036){ref-type="ref"}                                                Korea          NR             ROS            7     245   245   Surgery              I--III    154         91       --                            IHC        Scoring = 2          Monoclonal, rabbit anti‐human PTEN   39                 64         OS       Negative
  Hu *et al.* 2012[37](#tca12425-bib-0037){ref-type="ref"}                                                 China          2006--2007     ROS            6     114   114   Surgery              I--IV     74          40                                     IHC        50%                  Monoclonal, rabbit anti‐human PTEN   40.1               NR         OS       Positive
  An *et al.* 2012[38](#tca12425-bib-0038){ref-type="ref"}                                                 China          2004--2006     ROS            6     98    98    Surgery              I--IV     62          24       12                            IHC        Scoring = 0          Monoclonal, rabbit anti‐human PTEN   53.9               56.7       OS       Positive
  O\'Byrne *et al.* 2011[†](#tca12425-note-0002){ref-type="fn"} [39](#tca12425-bib-0039){ref-type="ref"}   Multi‐Center   2004--2006     ROS            7     155   155   CT                   III‐IV    69          52       27                            FISH       --                   --                                   NR                 NR         OS,DFS   Negative
  O\'Byrne *et al.* 2011[‡](#tca12425-note-0003){ref-type="fn"} [39](#tca12425-bib-0039){ref-type="ref"}   Multi‐Center   2004--2006     ROS            7     148   148   CT+ Cet              III--IV   63          59       33                            FISH       --                   --                                   NR                 NR         OS,DFS   Negative
  Zolota *et al.* 2010[40](#tca12425-bib-0040){ref-type="ref"}                                             Greece         2000--2006     ROS            7     128   46    Surgery              I--IV     64          46       --                            IHC        50%                  NR                                   23                 63         OS       Negative
  Yoshizawa *et al.* 2010[41](#tca12425-bib-0041){ref-type="ref"}                                          USA            NR             ROS            6     300   252   Surgery              I--IV     135         132      --                            IHC        Scoring = 2          Monoclonal, rabbit anti‐human PTEN   40.8               64.5       OS       Negative
  Wang *et al.* 2009[42](#tca12425-bib-0042){ref-type="ref"}                                               China          NR             ROS            6     249   249   Surgery              I--III    249         --       --                            IHC        5%                   Monoclonal, rabbit anti‐human PTEN   NR                 59.4       OS       Positive
  Regina *et al.* 2009[43](#tca12425-bib-0043){ref-type="ref"}                                             France         2002--2005     ROS            6     53    49    Surgery              I--IV     32          13       8                             PCR        --                   ‐                                    35                 66         OS       Negative
  Zheng *et al.* 2007[44](#tca12425-bib-0044){ref-type="ref"}                                              Japan          1993--2006     ROS            7     155   143   Surgery              I--IV     86          37       32                            IHC        5%                   Monoclonal, mouse anti‐human PTEN    20.6               69.5       OS       Positive
  Lim *et al.* 2007 I[45](#tca12425-bib-0045){ref-type="ref"}                                              Singapore      1998--2000     ROS            6     69    34    Surgery              I         13          20       1                             IHC        Scoring = 2          Polyclonal, rabbit anti‐human PTEN   NR                 67         /        /
  Lim *et al.* 2007 IV[45](#tca12425-bib-0045){ref-type="ref"}                                             Singapore      2000--2004     ROS            6     270   25    Gefitinib            IV        9           10       6                             IHC        Scoring = 2          Polyclonal, rabbit anti‐human PTEN   NR                 67         OS,DFS   Positive
  Tang *et al.* 2006[46](#tca12425-bib-0046){ref-type="ref"}                                               China          1997--1998     ROS            7     102   102   Surgery              I--IV     51          51       --                            IHC        Scoring = 2          Monoclonal, mouse anti‐human PTEN    NR                 59         OS       Positive
  Endoh *et al.* 2006[47](#tca12425-bib-0047){ref-type="ref"}                                              Japan          2002--2004     ROS            6     79    78    Surgery +Gefitinib   I--IV     68          6        4                             PCR        --                   --                                   NR                 61.9       OS       Negative

Patients treated with chemotherapy.

Patients treated with chemotherapy + cetuximab.

ADC, adenocarcinoma; Cet, cetuximab; CT, chemotherapy; DFS, disease‐free survival; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; N, number of patients included in the study; n, number of tests of PTEN to analyze survival outcome; NR, no referred; NOS, Newcastle--Ottawa Scale; OS, overall survival; PTEN, phosphatase and tensin homolog; ROS, retrospective observational study; RT, reverse transcription; SCC, squamous cell carcinoma.

Quality assessments of individual studies are shown in Table S1. We used the NOS for cohort studies to assess included studies, which included three aspects (selection, comparability, and outcome) and eight items. All studies scored either six or seven.

Correlation between phosphatase and tensin homolog (PTEN) expression and clinicopathological characteristics {#tca12425-sec-0015}
------------------------------------------------------------------------------------------------------------

The studies that referred to a correlation between PTEN expression and clinical characteristics were gathered to evaluate the combined ORs. We found that PTEN expression was significantly correlated with gender (male vs. female: OR 0.59, 95% CI 0.47--0.75; *P* = 0.000), smoking history (yes vs. no: OR 2.22, 95% CI 1.57--3.14; *P* = 0.000), histology (ADC vs. squamous cell carcinoma \[SCC\]: OR 1.53, 95% CI 1.03--2.29; *P* = 0.037), TNM stage (I--II vs. III--IV: OR 1.96, 95% CI 1.13--3.40; *P* = 0.017), N status (N0 vs. N1--N3: OR 2.22, 95% CI 1.31--3.76; *P* = 0.003), and distant metastasis (M0 vs. M1: OR 6.47, 95% CI 2.19--19.14; *P* = 0.001) (Table [2](#tca12425-tbl-0002){ref-type="table-wrap"}).

###### 

Meta‐analyses of PTEN expression classified by clinicopathological characteristics

  Clinical characteristics           N    Patients   Heterogeneity (I‐squared, *P*) (%)   Model    OR (95% CI)          *P*     Conclusion
  ---------------------------------- ---- ---------- ------------------------------------ -------- -------------------- ------- -----------------
  Gender (male vs. female)           10   1628       13.0                                 Fixed    0.59 (0.47--0.75)    0.000   Significant
  Age (\> 60 vs. ≤ 60)               5    608        0.0                                  Fixed    0.90 (0.60--1.35)    0.619   Not significant
  Smoking history (yes vs. no)       4    707        50.0                                 Fixed    2.22 (1.57--3.14)    0.000   Significant
  Histology (ADC vs. SCC)            12   1763       63                                   Random   1.53 (1.03--2.29)    0.037   Significant
  TNM stage (I--II vs. III--IV)      9    1220       70.9                                 Random   1.96 (1.13--3.40)    0.017   Significant
  Grade (G3 vs. G1--G2)              7    880        73.6                                 Random   0.76 (0.37--1.57)    0.455   Not significant
  pT stage (T1 vs. T2--T4)           5    816        51                                   Random   1.41 (0.79--2.49)    0.244   Not significant
  N status (N0 vs. N1--N3)           8    963        69.7                                 Random   2.22 (1.31--3.76)    0.003   Significant
  Distant metastasis (M0 vs. M1)     3    272        0.0                                  Fixed    6.47 (2.19--19.14)   0.001   Significant
  Vascular invasion (yes vs. no)     1    155        --                                   --       0.27 (0.10--0.68)    0.001   Significant
  Pleural involvement (yes vs. no)   1    155        --                                   --       3.60 (1.36--9.55)    0.001   Significant

ADC, adenocarcinoma; CI, confidence interval; N, reference count; N status, lymph node metastasis status; OR, odds ratio; pT, primary tumor; PTEN, phosphatase and tensin homolog; SCC, squamous cell carcinoma; TNM, tumor node metastasis; --, no data.

Correlation between PTEN expression and survival outcomes {#tca12425-sec-0016}
---------------------------------------------------------

All articles, including 2486 patients, listed the relationship between PTEN expression and survival outcome in NSCLC.[29](#tca12425-bib-0029){ref-type="ref"}, [30](#tca12425-bib-0030){ref-type="ref"}, [31](#tca12425-bib-0031){ref-type="ref"}, [32](#tca12425-bib-0032){ref-type="ref"}, [33](#tca12425-bib-0033){ref-type="ref"}, [34](#tca12425-bib-0034){ref-type="ref"}, [35](#tca12425-bib-0035){ref-type="ref"}, [36](#tca12425-bib-0036){ref-type="ref"}, [37](#tca12425-bib-0037){ref-type="ref"}, [38](#tca12425-bib-0038){ref-type="ref"}, [39](#tca12425-bib-0039){ref-type="ref"}, [40](#tca12425-bib-0040){ref-type="ref"}, [41](#tca12425-bib-0041){ref-type="ref"}, [42](#tca12425-bib-0042){ref-type="ref"}, [43](#tca12425-bib-0043){ref-type="ref"}, [44](#tca12425-bib-0044){ref-type="ref"}, [45](#tca12425-bib-0045){ref-type="ref"}, [46](#tca12425-bib-0046){ref-type="ref"}, [47](#tca12425-bib-0047){ref-type="ref"} The combined HR was 0.51 (95% CI 0.42--0.62; *P* = 0.000, I^2^ = 59.5%) for OS in 16 studies (Fig [3](#tca12425-fig-0003){ref-type="fig"}),[29](#tca12425-bib-0029){ref-type="ref"}, [30](#tca12425-bib-0030){ref-type="ref"}, [31](#tca12425-bib-0031){ref-type="ref"}, [32](#tca12425-bib-0032){ref-type="ref"}, [36](#tca12425-bib-0036){ref-type="ref"}, [37](#tca12425-bib-0037){ref-type="ref"}, [38](#tca12425-bib-0038){ref-type="ref"}, [39](#tca12425-bib-0039){ref-type="ref"}, [40](#tca12425-bib-0040){ref-type="ref"}, [41](#tca12425-bib-0041){ref-type="ref"}, [42](#tca12425-bib-0042){ref-type="ref"}, [43](#tca12425-bib-0043){ref-type="ref"}, [44](#tca12425-bib-0044){ref-type="ref"}, [45](#tca12425-bib-0045){ref-type="ref"}, [46](#tca12425-bib-0046){ref-type="ref"}, [47](#tca12425-bib-0047){ref-type="ref"} but was 0.82 (95% CI 0.26--2.60; *P* = 0.733, I^2^ = 84.7%) for DFS in three studies (Fig [4](#tca12425-fig-0004){ref-type="fig"}; Table [3](#tca12425-tbl-0003){ref-type="table-wrap"}).[33](#tca12425-bib-0033){ref-type="ref"}, [34](#tca12425-bib-0034){ref-type="ref"}, [35](#tca12425-bib-0035){ref-type="ref"} Negative PTEN expression was a predictor of poor OS (but not DFS) in NSCLC patients. We also conducted subgroup analysis according to region, sample size, follow‐up period, test methods, and NOS scores (Table [4](#tca12425-tbl-0004){ref-type="table-wrap"}). Interestingly, we found that the patients with positive PTEN tended to have favorable OS in Asian countries (HR 0.46, 95% CI 0.40--0.53; *P* = 0.027) compared with Western countries (HR 0.82, 95% CI 0.52--1.30; *P* = 0.319). Four trials for ADC and three for SCC were assessable for OS (Fig [3](#tca12425-fig-0003){ref-type="fig"}, Table [3](#tca12425-tbl-0003){ref-type="table-wrap"}). The combined HR for OS in ADC (95% CI) was 0.61 (0.44, 0.85; I^2^ = 0.0%, *P* = 0.003); however, the combined HR for OS in SCC (95% CI) was 0.78 (0.54, 1.12; I^2^ = 40.7%, *P* = 0.178). Moderate heterogeneity was found in the meta‐analysis for HR (OS) of the prognostic role of PTEN expression. Univariable meta‐regression was used to identify the source of heterogeneity, and we found that different regions (Asian vs. Western countries) could explain 53.1% of the heterogeneity (*P* = 0.039), which is consistent with the earlier result in OS subgroup analysis. However, published year (*P* = 0.942), NOS score (*P* = 0.506), and TNM stage (*P* = 0.388) could not explain the heterogeneity.

![Pooled hazard ratios (HRs) for assessing the prognostic value of phosphatase and tensin homolog expression for overall survival in (**a**) non‐small cell lung cancer, (**b**) adenocarcinoma, and (**c**) squamous cell carcinoma. †Patients treated with chemotherapy; ‡patients treated with chemotherapy + cetuximab. CI, confidence interval; D+L, DerSimonian & Laird; I--V, inverse variance.](TCA-8-203-g004){#tca12425-fig-0003}

![Pooled hazard ratios (HRs) for assessing the prognostic value of PTEN expression for DFS in surgical patients.](TCA-8-203-g001){#tca12425-fig-0004}

###### 

Meta‐analyses of PTEN expression to predict survival outcome in NSCLC patients

  Tumor type   Outcome   N     Patients       Heterogeneity (I^2^, *P*)   Model              HR (95% CI)        *P*        Conclusion
  ------------ --------- ----- -------------- --------------------------- ------------------ ------------------ ---------- ------------
  NSCLC        OS        16    2181           59.5%, 0.001                Random             0.53 (0.47,0.60)   0.000      Positive
  DFS          3         271   84.7%, 0.001   Random                      0.82 (0.26,2.60)   0.733              Negative   
  ADC          OS        4     504            0.0%, 0.949                 Fixed              0.61 (0.44,0.85)   0.003      Positive
  SCC          OS        3     321            40.7%, 0.185                Fixed              0.78 (0.54,1.12)   0.178      Negative

ADC, adenocarcinoma; CI, confidence interval; DFS, disease‐free survival; HR, hazard ratio; NSCLC, non‐small cell lung cancer; N, reference count, OS, overall survival; PTEN, phosphatase and tensin homolog; SCC, squamous cell carcinoma.

###### 

Subgroup analyses of the relationships between PTEN expression and overall survival

  Comparison variables   Number of studies (I^2^ statistics %)   HR (95% CI), *P*           Heterogeneity between sub‐groups (*P*)
  ---------------------- --------------------------------------- -------------------------- ----------------------------------------
  Total                  16 (59.5%)                              0.51 (0.42--0.62), 0.000   NA
  Regions                                                                                   0.000
  Asian countries        12 (48.1%)                              0.49 (0.40--0.53), 0.000   
  Western countries      3 (12.6%)                               0.82 (0.52--1.30), 0.399   
  Multi‐countries        1 (NA)                                  0.78 (0.61--1.01), 0.064   
  Sample size                                                                               0.017
  \>100                  8 (69.7%)                               0.57 (0.50--0.64), 0.000   
  ≤100                   8 (0.0%)                                0.40 (0.31--0.52), 0.000   
  Follow‐up period                                                                          0.565
  Referred               7 (74.3%)                               0.56 (0.46--0.67), 0.000   
  Not referred           9 (37.6%)                               0.52 (0.45--0.60), 0.000   
  Test method                                                                               0.001
  IHC                    13 (55%)                                0.48 (0.42--0.55), 0.000   
  Others                 3 (0%)                                  0.76 (0.59--0.97), 0.027   
  NOS score                                                                                 0.053
  ≤6                     10 (59.2%)                              0.48 (0.41--0.56), 0.000   
  \>6                    6 (56.6%)                               0.60 (0.51--0.71), 0.000   

CI, confidence interval; HR, hazard ratio; ICH, immunohistochemistry; NA, not applicable; NOS, Newcastle--Ottawa Scale; PTEN, phosphatase and tensin homolog.

Assessment of publication bias {#tca12425-sec-0017}
------------------------------

Publication bias is a major concern for all forms of meta‐analyses, because positive results tend to be accepted by journals while negative results are often rejected or are not even submitted. Two methods, including Begg\'s funnel plot and Egger\'s test, were used to evaluate publication bias of the meta‐analysis. No publication bias of the prognostic value of PTEN for OS in NSCLC was discovered (Fig [5](#tca12425-fig-0005){ref-type="fig"}). Both the Begg\'s test (*P* = 0.112) and the Egger\'s test (*P* = 0.272) found little publication bias. Although little publication bias was detected in our study, we caution the poor sensitivity of Begg\'s and Egger\'s tests when the number of eligible articles is fewer than 20.

![Publication bias of the prognostic value of phosphatase and tensin homolog for overall survival in non‐small cell lung cancer on Begg\'s and Egger\'s plots. SE, standard error.](TCA-8-203-g003){#tca12425-fig-0005}

Discussion {#tca12425-sec-0018}
==========

Phosphatase and tensin homolog, regarded as a tumor suppressor gene, regulates many cellular processes, including proliferation, survival, energy metabolism, cellular architecture, and motility.[48](#tca12425-bib-0048){ref-type="ref"} PTEN inactivation is frequently found in many tumors, including lung, endometrial, bladder, renal, and breast cancers.[49](#tca12425-bib-0049){ref-type="ref"} We found that PTEN expression was markedly lower in patients with certain clinicopathological characteristics, including men, SCC (vs. ADC), late N status (N1--N3), distant metastasis, and late TNM stage (stage III--IV), which implied that a loss of PTEN expression tended occur in late NSCLC stage and indicated a poor prognosis. No association was found between PTEN expression and age, grade, or primary tumor stage.

In the present meta‐analysis, we combined 19 published studies including 2486 patients with NSCLC to yield summary statistics, which indicate that negative expression of PTEN has a significant correlation with poorer OS in NSCLC; however, it is not an unfavorable prognostic factor for DFS in NSCLC patients. In subgroup analysis, we found that loss of PTEN expression only predicted adverse clinical outcomes in ADC patients. Interestingly, when we investigated survival by different regions, the poorer OS associated with PTEN loss was only observed in Asian patients. Thus, our results suggest that loss of PTEN expression was a more appropriate prognostic marker for ADC or Asian patients than for SCC or Western patients. However, further studies are required to address this issue.

Our study has several limitations. First, the findings of a meta‐analysis depend on the quality of the individual studies, as their potential problems and biases may affect the pooled data. According to the NOS quality assessment performed, 10 of the 16 involved studies scored six, and the other six scored seven, which indicated moderate quality of all of the studies. Second, the method of HR extrapolation is potentially biased. If the authors did not report the required statistics, we calculated them from the data available in the article; if this was not possible, we extrapolated them from the survival curves; therefore some subjective data may affect the final conclusion. Third, we did not search unpublished and grey literature databases, which may lead to potential publication bias. Furthermore, there is also a language bias, as we only screened English and Chinese literature.

In conclusion, this meta‐analysis implied that a loss of PTEN expression, which is associated with gender, smoking history, histology, TNM stage, N status, and distant metastasis, might play an unfavorable prognostic role for overall survival in NSCLC patients, especially Asian or ADC patients. However, there is moderate heterogeneity between the studies and further rigorous and high‐quality investigation of the effectiveness of PTEN as a therapeutic target for NSCLC is warranted.
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**Table S1** Quality assessment of individual studies using the Newcastle‐Ottawa Scale for cohort studies
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Click here for additional data file.
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